Boundless Bio (BOLD) Stock: Buy, Sell, or Hold?
BOLD - Boundless Bio, Inc. Common Stock
$2.35
-0.04 (-1.67%)
▼
5d:
-8.91%
30d:
-16.67%
90d:
-5.24%
WAIT
LOW Confidence
Analysis Updated: Oct 15, 2026 12:00 AM ET
Earnings: Nov 04, 2026
18d
Get Alerted When BOLD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BOLD shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BOLD shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: BOLD is currently trading at $2.35, which is considered oversold relative to its 30-day fair value range of $2.51 to $2.82.
Technical Outlook: Technically, BOLD is in a strong uptrend. The price is currently testing key support at $2.33. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BOLD scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+70.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BOLD is in a strong uptrend. The price is currently testing key support at $2.33. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BOLD scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+70.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.51 -
$2.82
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 70.2% below Wall St target ($4.00)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.51 -
$2.82
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.34
Resistance Level
$2.71
Current Trend
Strong Uptrend
Technical data as of
Oct 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.40
Wall Street Target
$4.00
(+70.2%)
Share & Embed Analysis
Last updated: October 16, 2026 2:49 AM ET
Data refreshes hourly during market hours. Next update: 3:49 AM
Data refreshes hourly during market hours. Next update: 3:49 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BOLD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
27 analysts |
$92 | 66 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$285 | 58 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$109 | 65 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$129 | 72 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
17 analysts |
$37 | 68 BUY |
